Therefore, it seems likely that high HLA-E expression will also limit NK cell anti-breast-cancer responses, and in those cases, blocking antibodies such as the anti-NKG2A antibody monalizumab might need to be considered. This evidence concerns the gene KLRC1 and breast cancer.